Astrana Health, Inc. (ASTH)

Environment story

Astrana Health disclosed minimal environmental data in its 2025 10-K filing. No Scope 1, Scope 2, or Scope 3 emissions figures are reported. No net-zero target year is disclosed. No renewable energy percentage is stated. No material environmental controversies, lawsuits, or fines related to toxic waste, water consumption, or habitat damage are noted in the filing. The company's healthcare operations (clinics, hospitals, labs, pharmacies) generate operational emissions typical of the sector, but quantification and mitigation strategies are absent from public disclosures. Absence of disclosed environmental commitments and metrics prevents higher scoring; healthcare-sector baseline operations and lack of documented violations prevent lower scoring.

Social story

Astrana Health employs approximately 3,000 employees as of December 31, 2025, with no unionized workforce and no documented work stoppages. The 10-K states commitment to competitive compensation, professional development, and safe/inclusive workplace, but does not disclose CEO-to-median-worker pay ratio, workforce diversity percentages, or leadership diversity metrics. No active documented union-suppression activities or major strikes within 24 months are reported. The company highlights charitable contributions (Susan G. Komen, Eisner Health) and volunteer participation, as well as internal learning and development programs and professional development reimbursement. Supply-chain labor practices are not discussed in the filing. The absence of disclosed diversity data and pay-equity metrics, combined with lack of transparency on supply-chain audits, prevents higher scoring. No overt labor violations or litigation are documented.

Governance story

Astrana Health is a large accelerated filer on Nasdaq (ASTH) with approximately 55.6 million common shares outstanding as of March 5, 2026. The 10-K does not disclose board independence percentage, share structure (single or dual-class), or annual lobbying expenditures. No active antitrust proceedings, consumer-safety litigation, or financial-fraud regulatory actions are disclosed in the filing. The company acknowledges a material weakness in internal control over financial reporting (disclosed in Item 9A context), which is a governance concern but not a direct antitrust or securities fraud violation. No evidence of shareholder litigation, climate-proposal blocking, or anti-consumer lobbying is documented in the filing. The absence of disclosed board independence metrics, share-structure details, and lobbying spend, combined with the disclosed material weakness, prevents higher scoring. No major regulatory fines or consent decrees are reported.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Astrana Health, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Astrana Health, Inc. in the app for interactive charts and portfolio building.

More in Healthcare